# iPLATO Healthcare

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iplato-healthcare

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.iplato.net
- Total disclosed funding: $0.4M
- Latest round: Series A (Mar 21, 2006)
- Investors on record: 1

## About

iPLATO Healthcare Ltd is a London-based company specializing in innovative technology solutions that enhance primary care and population health through effective patient engagement and streamlined healthcare pathways.iPLATO Healthcare Ltd, founded in 2006 in London, UK, focuses on providing a unified technology platform to optimize primary care. The company has undergone strategic pivots to enhance its offerings. In January 2022, iPLATO was acquired by Huma Therapeutics Limited, a portfolio company of Bayer AG, from YFM Venture Finance Limited. The total amount raised throughout its history is GBP 0.250 mn, with the latest funding round being a Series A that occurred in January 2022, which involved YFM Venture Finance Limited as the investor. The current CEO is Tobias Alpsten.iPLATO's primary offerings center around a unified technology platform designed to enhance primary care and population health through innovative, multi-channel patient engagement. The core products include the myGP app, which enables health-conscious patients to manage their healthcare more effectively, and a suite of solutions that streamline patient pathways across fragmented healthcare systems. These offerings are deployed by NHS payers and utilized by a network of GP surgeries, aiming to empower millions of patients and caregivers. The solutions specifically target challenges such as health inequalities and the overburdening of healthcare services by facilitating better collaboration among clinicians and care professionals. iPLATO serves clients across the United Kingdom and the Czech Republic, focusing on the needs of both healthcare providers and patients within these geographical markets.In 2021, iPLATO reported a revenue of GBP 5,859,863, while the EBITDA for the same year was GBP -3,319,512.9. The company's revenue model is structured around a combination of subscription services and partnerships with healthcare providers, including NHS entities and private GP practices. Clients pay for access to the platform and its capabilities, which include features like patient questionnaires, population health engagement tools, and digital front-door solutions. The company’s flagship offerings, such as the myGP app and the Patient Network, are key components of their revenue stream, catering primarily to B2B relationships with healthcare organizations.iPLATO aims to leverage recent funding to enhance product offerings, focusing on new developments in its technology platform. The company is exploring expansion into additional European markets, with strategic plans in place to target specific regions by the end of 2023. The funding received in January 2022 will support these initiatives, enabling iPLATO to further develop its product line and reach a broader audience.

## Funding rounds

- Series A, Mar 21, 2006, $0.4M — YFM Venture Finance Limited

## Investors

- YFM Venture Finance Limited (https://capitalatlas.ai/funds/yfm-venture-finance-limited) — Series A